Key facts
- It has raised $4.4M; the latest was Early Stage VC ($4.4M) in Dec 2024.
- Notable investors include Accelerate@Babraham, Delin Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Athernal Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Athernal Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Athernal Bio
Developer of targeted immunotherapy treatments designed for early intervention in blood-cancer precursor conditions. The company is developing a platform that focuses on identifying and removing mutation-bearing haematopoietic stem cell clones associated with clonal haematopoiesis, enabling healthcare markets to address cancer-initiating processes through features such as mutation-specific target selection, immune-driven cell clearance, precision delivery technologies and programmes spanning rare disorders, treatment-related injury and age-related clonal expansion.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2024
- Website
- athernalbio.com/
- Ownership
- Privately Held (backing)
Athernal Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Athernal Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Athernal Bio in its N-PORT filings yet. We sweep new filings monthly.